Safety and Effectiveness of Two Different Formulations of an HIV Vaccine in Infants Born to HIV-Infected Women

National Institute of Allergy and Infectious Diseases (NIAID)

Overview

The purpose of this study is to test the safety and effectiveness of two different formulations of an HIV vaccine in infants born to HIV-infected women.

Study Type

INTERVENTIONAL

Purpose

PREVENTION

Conditions

HIV Infections HIV Seronegativity

Interventions

Aluminum hydroxideBIOLOGICAL

QS-21BIOLOGICAL

MN rsgp120/HIV-1BIOLOGICAL

Eligibility

Sex: ALLMin age: 1 DayMax age: 3 DaysHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria Infants may be eligible for this study if they: * Are 1 to 3 days old.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.